<DOC>
	<DOCNO>NCT02343133</DOCNO>
	<brief_summary>The purpose study determine whether HemaMax safe well tolerated support efficacy FDA 's Animal Rule reduce morbidity mortality associate hematopoietic syndrome acute radiation syndrome .</brief_summary>
	<brief_title>Safety Study HemaMax™ ( rHuIL-12 ) Treat Acute Radiation Syndrome</brief_title>
	<detailed_description>This phase 2 single dose , randomize , double-blind , placebo-controlled , multi center study evaluate safety , tolerability , pharmacokinetics pharmacodynamics HemaMax™ ( rHuIL-12 ) healthy adult male female subject consider representative U.S. population .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Radiation Syndrome</mesh_term>
	<mesh_term>Radiation Injuries</mesh_term>
	<criteria>Male Female healthy subject sign informed consent form must meet follow criterion ≥18 ≤75 year age Body mass index ( BMI ) ≥ 18 ≤ 35 kg/m2 Normal ECG , vital sign laboratory test result Use effective birth control method abstinence sex Negative pregnancy test drug screen Subjects follow characteristic consider ineligible : History clinically significant renal , hepatic pulmonary , cardiovascular , cerebrovascular , gastrointestinal , metabolic , hematological , endocrine , urological , immunological , neurologic psychiatric disorder connective tissue disease Positive human immunodeficiency virus ( HIV ) , Hepatitis B , surface antigen ( HBsAg ) Hepatitis C antibody , tuberculosis ( TB ) Drug alcohol addiction History clinically significant allergy kind Prior use IL12 HemaMax Use approve investigational biologic agent vaccination kind last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Radiation countermeasure</keyword>
	<keyword>radiomitigation</keyword>
</DOC>